In addition, panobinostat, a pan-histone deacetylase inhibitor with intrinsic anti-myeloma activity, was also shown to increase CD38 expression on MM cells, leading to increased ADCC (but not CDC) of primary MM cells induced by daratumumab [72]. The gene discussed is CD38; the disease is plasma cell myeloma.